Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study

Franco Locatelli(Bambino Gesù Children's Hospital), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Annie St. Pierre(Novartis (Switzerland)), Christine Rosko(Novartis (United States)), K. Burock(Bayer (United States)), Katsuyoshi Koh(Saitama Children's Medical Center), Alphan Küpesiz(Akdeniz University), Bülent Antmen(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Ho Joon Im(Ulsan College), Yogi Chopra(Hospital for Sick Children), Hyoung Jin Kang(Seoul National University Hospital), Sunil Bhat(Narayana Health), Yoshiyuki Takahashi(Nagoya University), Tayfun Güngör, Maria Gabriela Matos(Support group for adolescents and children with cancer), Tommaso Stefanelli(Novartis (Switzerland)), Meng‐Yao Lu(National Taiwan University Hospital), Yvonne S. Smith(Novartis (Ireland)), Karen Sinclair(Novartis (Switzerland))
The Lancet Haematology
July 10, 2024
Cited by 18


Related Papers